Inhibikase Therapeutics (IKT) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	IKT
Entity Registrant Name	INHIBIKASE THERAPEUTICS, INC.
Entity Central Index Key	0001750149
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		25,155,198
Entity File Number	001-39676
Entity Current Reporting Status	Yes
Entity Tax Identification Number	26-3407249
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	678
Local Phone Number	392-3419
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 44,845,950	$ 13,953,513
Grants receivable	217,482
Prepaid research and development	264,381	774,356
Prepaid expenses and other current assets	541,388	54,837
Total assets	45,869,201	14,782,706
Current liabilities:
Accounts payable	553,801	1,720,680
Accrued expenses and other current liabilities	1,905,010	632,934
Deferred revenue	0	2,325,741
Notes payable	248,911	42,534
Total	2,707,722	4,721,889
Notes payable, net of current portion	0	276,461
Total liabilities	2,707,722	4,998,350
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020
Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,155,198 and 10,050,849 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.	25,155	10,051
Additional paid-in capital	67,912,392	24,805,929
Accumulated deficit	(24,776,068)	(15,031,624)
Total	43,161,479	9,784,356
Total liabilities and stockholders' equity	$ 45,869,201	$ 14,782,706

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	30,000,000
Common stock, shares issued	25,155,198	10,050,849
Common stock, shares outstanding	25,155,198	10,050,849

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 328,459	$ 37,680	$ 3,098,661	$ 528,052
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember
Costs and expenses:
Research and development	$ 3,154,553	$ 120,569	$ 7,968,846	$ 666,858
Selling, general and administrative	1,644,946	580,820	4,854,494	1,478,839
Total costs and expenses	4,799,499	701,389	12,823,340	2,145,697
Loss from operations	(4,471,040)	(663,709)	(9,724,679)	(1,617,645)
Interest expense	(157)	(6,890)	(19,765)	(22,263)
Net loss	$ (4,471,197)	$ (670,599)	$ (9,744,444)	$ (1,639,908)
Net loss per share – basic and diluted	$ (0.18)	$ (0.08)	$ (0.61)	$ (0.20)
Weighted-average number of common shares – basic and diluted	25,143,559	8,198,754	15,868,421	8,187,517

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Deficit) - USD ($)	Total	June 2021 Offering	Common Stock	Common StockJune 2021 Offering	Additional Paid-In Capital	Additional Paid-In CapitalJune 2021 Offering	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ (4,490,016)		$ 8,181		$ 7,685,533		$ (12,183,730)
Beginning balance, Shares at Dec. 31, 2019			8,180,937
Stock-based compensation expense	139,758				139,758
Warrant expense/ Issuance of warrants	190,993				190,993
Issuance of common stock	4,871		$ 1		4,870
Issuance of common stock, Shares			874
Net loss	(547,440)						(547,440)
Ending balance at Mar. 31, 2020	(4,701,834)		$ 8,182		8,021,154		(12,731,170)
Ending balance, Shares at Mar. 31, 2020			8,181,811
Beginning balance at Dec. 31, 2019	(4,490,016)		$ 8,181		7,685,533		(12,183,730)
Beginning balance, Shares at Dec. 31, 2019			8,180,937
Warrant expense/ Issuance of warrants	$ 516,923
Issuance of common stock, stock options exercised, Shares	95,349
Net loss	$ (1,639,908)
Ending balance at Sep. 30, 2020	(5,125,056)		$ 8,207		8,690,375		(13,823,638)
Ending balance, Shares at Sep. 30, 2020			8,206,706
Beginning balance at Mar. 31, 2020	(4,701,834)		$ 8,182		8,021,154		(12,731,170)
Beginning balance, Shares at Mar. 31, 2020			8,181,811
Stock-based compensation expense	139,759				139,759
Warrant expense/ Issuance of warrants	89,515				89,515
Conversion of notes	63,800		$ 11		63,789
Conversion of notes, Shares			11,594
Net loss	(421,869)						(421,869)
Ending balance at Jun. 30, 2020	(4,830,629)		$ 8,193		8,314,217		(13,153,039)
Ending balance, Shares at Jun. 30, 2020			8,193,405
Stock-based compensation expense	139,758				139,758
Warrant expense/ Issuance of warrants	236,415				236,415
Issuance of common stock, cashless warrant exercise	(1)		$ 14		(15)
Issuance of common stock, cashless warrant exercise, Shares			13,301
Net loss	(670,599)						(670,599)
Ending balance at Sep. 30, 2020	(5,125,056)		$ 8,207		8,690,375		(13,823,638)
Ending balance, Shares at Sep. 30, 2020			8,206,706
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		24,805,929		(15,031,624)
Beginning balance, Shares at Dec. 31, 2020	10,050,849		10,050,849
Stock-based compensation expense	$ 591,124				591,124
Warrant expense/ Issuance of warrants	237,768				237,768
Issuance of common stock	60,391		$ 9		60,382
Issuance of common stock, Shares			9,000
Net loss	(2,637,068)						(2,637,068)
Ending balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203		(17,668,692)
Ending balance, Shares at Mar. 31, 2021			10,059,849
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		24,805,929		(15,031,624)
Beginning balance, Shares at Dec. 31, 2020	10,050,849		10,050,849
Warrant expense/ Issuance of warrants	$ 658,945
Net loss	(9,744,444)
Ending balance at Sep. 30, 2021	$ 43,161,479		$ 25,155		67,912,392		(24,776,068)
Ending balance, Shares at Sep. 30, 2021	25,155,198		25,155,198
Beginning balance at Mar. 31, 2021	$ 8,036,571		$ 10,060		25,695,203		(17,668,692)
Beginning balance, Shares at Mar. 31, 2021			10,059,849
Stock-based compensation expense	322,483				322,483
Warrant expense/ Issuance of warrants	239,415				239,415
Issuance of common stock		$ 41,135,357		$ 15,000		$ 41,120,357
Issuance of common stock, Shares				15,000,000
Issuance of common stock, stock options exercised	(43,295)		$ 74		(43,369)
Issuance of common stock, stock options exercised, Shares			73,496
Net loss	(2,636,179)						(2,636,179)
Ending balance at Jun. 30, 2021	47,054,352		$ 25,134		67,334,089		(20,304,871)
Ending balance, Shares at Jun. 30, 2021			25,133,345
Stock-based compensation expense	352,419				352,419
Warrant expense/ Issuance of warrants	181,762				181,762
Issuance of common stock, stock options exercised	44,143		$ 21		44,122
Issuance of common stock, stock options exercised, Shares			21,853
Net loss	(4,471,197)						(4,471,197)
Ending balance at Sep. 30, 2021	$ 43,161,479		$ 25,155		$ 67,912,392		$ (24,776,068)
Ending balance, Shares at Sep. 30, 2021	25,155,198		25,155,198

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss	$ (9,744,444)	$ (1,639,908)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,266,026	419,275
Non-cash consulting fees	60,391	112,500
Non-cash PPP loan forgiveness	(27,550)	0
Warrant expense	658,945	516,923
Changes in operating assets and liabilities:
Grants receivable	(217,482)	0
Prepaid expenses and other assets	(486,551)	3,218
Prepaid research and development	509,975	0
Accounts payable	(1,166,879)	1,046,755
Accrued expenses and other current liabilities	1,272,076	(1,171,508)
Deferred revenue	(2,325,741)	529,918
Net cash used in operating activities	(10,201,234)	(182,827)
Financing activities
Proceeds from notes payable	0	272,800
Proceeds from issuance of common stock	41,135,357	4,870
Deferred initial public offering costs	0	(97,132)
Issuance of common stock from exercise of stock options	78,500	0
Payment of employee taxes in connection with stock option exercise	(77,652)	0
Repayments of note payable	(42,534)	0
Net cash provided by financing activities	41,093,671	180,538
Net increase (decrease) in cash	30,892,437	(2,289)
Cash at beginning of period	13,953,513	18,457
Cash at end of period	44,845,950	16,168
Supplemental disclosures of cash flow information
Cash paid for interest	19,608	4,520
Non-cash financing activities
Notes payable settled with new notes payable	0	42,534
Notes payable settled with common stock	0	63,800
PPP loan forgiveness	27,550	0
Accrued deferred initial public offering costs	$ 0	$ 1,334,331

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Inhibikase Therapeutics, Inc. (the “Company,” “we” or “our”) is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or "PD", and related disorders that arise inside and outside of the brain. In 2021, we commenced clinical development of IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor we believe can modify the course of Parkinson’s disease and its manifestation in the gastrointestinal tract, or GI. Results to date of our ongoing Phase 1 Single and Multiple Ascending Dose escalation study ("SAD" and "MAD", respectively) in older and elderly healthy volunteers have revealed important insights into the safety, tolerability and pharmacokinetics of IkT-148009 in human subjects. Outcomes of this study led to an acceleration of the clinical development program. In July 2021, the U.S. Food and Drug Administration (“FDA”) agreed with the Company’s plan to initiate its Phase 1b study in Parkinson’s patients which commenced dosing October 19, 2021. Clinical development of IkT-148009 for the GI complications in PD patients will cross-reference the Phase 1 study of IkT-148009 for the treatment of PD. Clinical development of the Company’s lead oncology asset, IkT-001Pro, is anticipated to begin shortly after submission of Company’s Investigational New Drug application for IkT-001Pro; submission of the IND is anticipated to occur in the first quarter of 2022. The Company’s pursuit of the orphan indication Multiple System Atrophy is ongoing with regulators in the U.S. and Europe.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2021
Disclosure Of Liquidity And Going Concern [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company has recognized recurring losses. At September 30, 2021, the Company had working capital of $ 43,161,479 , an accumulated deficit of $ 24,776,068 , cash of $ 44,845,950 , accounts payable and accrued expenses of $ 2,458,811 and notes payable of $ 248,911 . The Company had active grants in the amount of $ 1,932,618 , of which $ 519,813 remained available in accounts held by the U.S. Treasury as of October 29, 2021. The future success of the Company is dependent on its ability to successfully obtain additional working capital, obtain regulatory approval for and successfully launch and commercialize its product candidates and to ultimately attain profitable operations. Historically, the Company has funded its operations primarily through cash received in connection with revenue from its various grant programs. In addition, in June 2021 and December 2020, the Company raised approximately $ 41.1 million and $ 14.6 million in working capital from its underwritten public offering (the “June 2021 Offering”) and its initial public offering (“IPO”), respectively. The Company is subject to a variety of risks similar to other early-stage life science companies including, but not limited to, the successful development, regulatory approval, and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional working capital. The Company has incurred significant research and development expenses and general and administrative expenses related to its product candidate programs. The Company anticipates costs and expenses to increase in the future as the Company continues to develop its product candidates. The Company may seek to fund its operations through additional public equity, private equity, or debt financings, as well as other sources. However, the Company may be unable to raise additional working capital, or if it is able to raise additional capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to continue to develop its product candidates. The Company estimates that its working capital at September 30, 2021 is sufficient to fund its normal operations into the first quarter of 2023. The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	3. Basis of Presentation and Significant Accounting Policies Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2020 balance sheet was derived from December 31, 2020 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2021. The condensed unaudited financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report filed on SEC Form 10-K. These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The condensed financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On August 21, 2020, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-1.14396 (1:1.14396) reverse stock split of its common stock, par value $ .001 per share, effective August 24, 2020. All warrant, option, share, and per share information in the Company’s financial statements gives retroactive effect to the one-for-1.14396 reverse stock split that was effected on August 24, 2020. The condensed financial statements have been prepared in conformity with US GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Concentrations of Credit Risk For the three months ended September 30, 2021 and 2020, the Company derived more than 90 % of its total revenue from a single source, the United States Government, in the form of federal research grants. Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s condensed statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Balance Sheet Information	4. Supplemental Balance Sheet Information Accrued expenses and other current liabilities consist of the following: September 30, December 31, Accrued consulting $ 256,342 $ 115,405 Accrued legal and professional fees — 383,286 Accrued research and development 1,483,479 83,491 Accrued interest 811 1,673 Accrued bonuses 152,860 — Accrued other 11,518 49,079 Total accrued expenses and other current liabilities $ 1,905,010 $ 632,934

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable Notes payable outstanding were $ 248,911 and $318,995 at September 30, 2021 and December 31, 2020, respectively. September 30, December 31, Fifth Restated Note $ — $ 42,534 PPP Note — 27,550 CEO Restated Note 248,911 248,911 Total notes payable $ 248,911 $ 318,995 Future principal payments on the notes payable as of September 30, 2021, are as follows:  Year ending December 31, 2021 $ — 2022 248,911 2023 — 2024 — 2025 — Total notes payable $ 248,911 Revolving Demand Promissory Note During 2019 and 2020, the Company entered into a series of promissory notes that were renegotiated and partially settled over 2019 and 2020. On January 1, 2020, the Company issued a note (the “2020 Note”) in the face amount of $ 103,586 bearing 5.25 % APR simple interest as settlement in full on the 2019 Note principal of $ 98,419 plus accrued interest of $ 5,167 that matured on January 1, 2020 . The 2020 Note was scheduled to mature on January 1, 2021 . Upon occurrence of certain conditions including the sale of a division of the Company or upon the date on which the Company closes on certain financings, the due date for some or all of the unpaid principal and accrued and unpaid interest may be accelerated. The Company assessed the terms and features of the 2020 Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 30, 2020, the holder of the 2020 Note and the Company entered into an agreement to settle the 2020 Note early. As full consideration and settlement of the 2020 Note’s June 30, 2020 principal balance plus accrued and unpaid interest in the amount of $ 106,334 , the Company issued a new promissory note to the holder in the amount of $ 42,534 (the “Fifth Restated Note”) with substantially similar terms as the 2020 Note. In addition, the holder subscribed for the purchase of 11,594 unregistered shares of the Company’s common stock at a subscription price of $ 63,800 , or $ 5.50 per share. The issuance of shares under the subscription agreement and the issuance of the Fifth Restated Note satisfied the payoff of the 2020 Note without premium or discount. The balance of the Fifth Restated Note was $ 42,534 on December 31, 2020 and is included in Notes payable. The Fifth Restated Note was scheduled to mature on the earlier of a significant transaction, including an initial public offering, sale of substantially all assets or change of control, or January 1, 2021. The Company consummated its IPO on December 28, 2020 and the principal balance of the Fifth Restated Note plus accrued and unpaid interest was settled in full in cash on January 1, 2021. Note Payable to CEO On February 5, 2020 (the “Issue Date”), the Company issued a note payable to its CEO (the “CEO Note”) in the face amount of $ 245,250 bearing 1.59 % APR simple interest in exchange for cash. The net proceeds of $ 245,250 were used as working capital by the Company. The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note. If an event of default occurs and is continuing, the Company agrees to issue a warrant to the holder with a strike price of $ 4.87 per share for a number of shares equal to 150 % of the value of the loan. The Company assessed the terms and features of the CEO Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 13, 2020, the holder of the CEO Note and the Company entered into a restated agreement (the “CEO Restated Note”). The CEO Restated Note in the amount of $ 248,911 extends the stated maturity date of the CEO Note from the earlier of the sixth month following the (original) Issue Date or the date the Company has sufficient funds to repay the note to the earlier of the 30th month following the (original) Issue Date or the date the Company has sufficient funds to repay the CEO Restated Note. The Issue Date, February 5, 2020 , is unchanged. In addition, the interest rate was reduced, effective as of the Issue Date, from 1.59 % APR to 0.25 %. The CEO Restated Note also changed the exercise price of the warrant from $ 4.87 to $ 4.81 per share in the case of any default. The other provisions of the CEO Restated Note are the same, in all material respects, to the CEO Note. The Company and its CEO have agreed that the CEO Restated Note will be repaid by the end of first half of 2022. The principal balance of the CEO Note was $ 248,911 at September 30, 2021 and at December 31, 2020 and is included on the condensed balance sheets in Notes payable at September 30, 2021 and Notes payable, net of current portion at December 31, 2020. The Paycheck Protection Program Loan (the “PPP Loan”) On May 4, 2020 the Company received $ 27,550 in loan proceeds as part of the Federal Coronavirus Aid, Relief and Economic Security Act Paycheck Protection Program (the “PPP Act” or “PPP”) with a 1 % annual interest rate. Some or all of this loan qualified for forgiveness if the Company expended not less than 60 % of the loan proceeds on qualified payroll costs. During the nine months ended September 30, 2021, it was determined by the lender and by the Small Business Administration that the Company met the contractual conditions for forgiveness of the entire PPP Loan plus accrued interest and it was forgiven. The $ 27,550 principal balance of the PPP Loan at December 31, 2020 is included on the condensed balance sheet in Notes payable, net of current portion.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2021
Stockholders Equity Note [Abstract]
Stockholders' Equity (Deficit)	6. Stockholders’ Equity (Deficit) Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. A tota l of 5,191,957 and 4,318,357 shares of common stock were reserved for issuance upon the exercise of outstanding stock options and warrants as of September 30, 2021 and December 31, 2020, respectively. Reverse Stock Split On August 20, 2020, the board of directors adopted resolutions proposing that each 1.14396 shares of the Company’s issued and outstanding common stock, par value $0.001 per share, be automatically converted into one fully paid and non-assessable share of common stock, par value $0.001 (the “Reverse Stock Split”) with cash in lieu of fractional shares. On August 21, 2020, shareholders representing a majority of the issued and outstanding common stock approved the Reverse Stock Split. On August 21, 2020, the Company filed with the Delaware Secretary of State its Certificate of Amendment to its Certificate of Incorporation, effective as of August 24, 2020. Share Issuances In January 2020, an accredited investor subscribed for, and the Company issued, 874 shares of its stock in a private placement transaction at a per share price of $ 5.57 . Net proceeds were approximately $ 4,870 . Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. During the nine months ended September 30, 2021 , an accredited investor subscribed for, and the Company issued, 9,000 shares of its stock in exchange for consulting services. The fair value of the stock was $ 60,391 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. The $ 60,391 fair value is a component of selling, general and administrative costs for the nine months ended September 30, 2021. During the nine months ended September 30, 2020 the Company iss ued 95,349 sha res of its stock in connection with the exercise of non-qualified stock options. In connection with the June 2021 Offering, the Company issued and sold 15,000,000 fully paid non-assessable shares of its common stock at a public offering price of $ 3.00 per share. Proceeds from the June 2021 Offering were $ 41.1 million after deducting offering costs, underwriting discounts and commissions of approximately $ 3.9 million. The net proceeds are and will be used as working capital by the Company.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation 2020 Equity Incentive Plan The Company’s 2020 Equity Incentive Plan (the “2020 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants to the Company. Stock Options During the nine months ended September 30, 2021, the Company granted 68,628 options to its scientific advisory board members with a strike price of $ 6.82 per share, vesting immediately, with an aggregate grant date fair value of $ 259,674 . On June 25, 2021, the Company granted a total of 90,708 options to members of its board of directors with a strike price of $ 2.92 per share, vesting one year from the date of the grant, with an aggregate grant date fair value of $ 160,000 . On August 16, 2021, the Company granted 27,240 employee stock options with a strike price of $ 1.79 per share, vesting in three equal annual installments commencing on the first anniversary of the grant date, with a grant date fair value of $ 50,000 . In May 2021, the Company issued 73,496 shares of its common stock in connection with the exercise of non-qualified stock options with a strike price of $ 0.38 per share. All such securities were issued without registration under the Securities Act of 1933, as amended, in reliance upon the exemption afforded by Section 4(a)(2) of that Act. In June 2021, the Company issued 21,854 shares of its common stock in connection with the exercise of non-qualified stock options with a strike price of $ 2.02 per share. All such securities were issued without registration under the Securities Act of 1933, as amended, in reliance upon the exemption afforded by Section 4(a)(2) of that Act. In August 2021, the Company issued 21,853 shares of its common stock in connection with the exercise of non-qualified stock options with a strike price of $ 2.02 per share. All such securities were issued without registration under the Securities Act of 1933, as amended, in reliance upon the exemption afforded by Section 4(a)(2) of that Act. No options were granted during the nine months ended September 30, 2020. Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Nine Months Ended September 30, 2021 2020 Research and development $ 592,966 $ 195,061 Selling, general and administrative 673,060 224,214 Total stock-based compensation expense $ 1,266,026 $ 419,275

Warrants

Warrants	9 Months Ended
	Sep. 30, 2021
Warrants And Rights Note Disclosure [Abstract]
Warrants	8. Warrants Warrants Issued On March 31, 2020, the Company issued a warrant to purchase up to 26,225 shares of its stock to one of its consultants in exchange for services. The warrant contains a strike price of $ 5.67 per share and has a seven-year contractual term. The warrant is classified within stockholders’ equity at its fair value and was treated as a standalone instrument. The fair value of the warrant was determined to be $ 101,478 utilizing the Black-Scholes-Merton option-pricing model at the time of issuance and is included in selling, general and administrative expenses for the nine months ended September 30, 2020. The Company recognized $ 658,945 in warrant expense for the nine months ended September 30, 2021, included in selling, general and administration expense. In connection with the June 2021 Offering the Company issued and sold to its underwriters a warrant to purchase up to 750,000 shares of its common stock for an aggregate purchase price of $ 100 pursuant to its written agreement with the underwriters. This warrant is exercisable beginning June 15, 2022 at an initial exercise price of $ 3.75 per share of common stock. Warrants Exercised No warrants were exercised for the nine months ended September 30, 2021 and 2020.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	9. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Nine Months Ended September 30, 2021 2020 Numerator: Net loss $ ( 9,744,444 ) $ ( 1,639,908 ) Denominator: Weighted-average number of common shares 15,868,421 8,187,517 Net loss per share applicable to common $ ( 0.61 ) $ ( 0.20 ) The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Nine Months Ended September 30, 2021 2020 Options to purchase shares of stock 3,630,044 3,369,144 Warrants to purchase shares of stock 1,561,913 650,948 Total 5,191,957 4,020,092

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes During the nine months ended September 30, 2021 and 2020, there was no provision for income taxes as the Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company recorded a full valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Impact of the COVID-19 Pandemic on Our Operations The novel coronavirus SARS-Cov2, or COVID-19, pandemic is causing significant, industry-wide delays in clinical trials. There are multiple causes of these delays, including reluctance of patients to enroll or continue in trials for fear of exposure to COVID-19, local and regional shelter-in-place orders and regulations that discourage, hamper, or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of COVID-19 patients and the FDA and other regulators making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to the pandemic. As a result of the COVID-19 pandemic, commencement of enrollment in our clinical trials may be delayed. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in the Company’s trials or are subject to isolation or shelter-in-place restrictions, this may cause them to drop out of the Company’s trials, miss scheduled doses or follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if the Company’s trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the Company’s trials may be compromised or not accepted by the FDA or other regulatory authorities, which could impact or delay a clinical development program. The Company anticipates that the COVID-19 pandemic may also impact manufacturing and distribution of materials necessary for conducting its clinical trials. Although the Company did not experience a material impact on its operations during the nine months ended September 30, 2021 and 2020, the Company notes the high level of difficulty in determining the future potential adverse financial impact and other effects of COVID-19 on the Company and its programs, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability would include probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation of Interim Financial Statements	Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2020 balance sheet was derived from December 31, 2020 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2021. The condensed unaudited financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report filed on SEC Form 10-K. These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The condensed financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On August 21, 2020, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-1.14396 (1:1.14396) reverse stock split of its common stock, par value $ .001 per share, effective August 24, 2020. All warrant, option, share, and per share information in the Company’s financial statements gives retroactive effect to the one-for-1.14396 reverse stock split that was effected on August 24, 2020. The condensed financial statements have been prepared in conformity with US GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk For the three months ended September 30, 2021 and 2020, the Company derived more than 90 % of its total revenue from a single source, the United States Government, in the form of federal research grants.
Revenue Recognition	Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s condensed statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: September 30, December 31, Accrued consulting $ 256,342 $ 115,405 Accrued legal and professional fees — 383,286 Accrued research and development 1,483,479 83,491 Accrued interest 811 1,673 Accrued bonuses 152,860 — Accrued other 11,518 49,079 Total accrued expenses and other current liabilities $ 1,905,010 $ 632,934

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Summary of Notes Payable	Notes payable outstanding were $ 248,911 and $318,995 at September 30, 2021 and December 31, 2020, respectively. September 30, December 31, Fifth Restated Note $ — $ 42,534 PPP Note — 27,550 CEO Restated Note 248,911 248,911 Total notes payable $ 248,911 $ 318,995
Summary of Future Principal Payments on Notes Payable	Future principal payments on the notes payable as of September 30, 2021, are as follows:  Year ending December 31, 2021 $ — 2022 248,911 2023 — 2024 — 2025 — Total notes payable $ 248,911

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees	The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Nine Months Ended September 30, 2021 2020 Research and development $ 592,966 $ 195,061 Selling, general and administrative 673,060 224,214 Total stock-based compensation expense $ 1,266,026 $ 419,275

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders	The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Nine Months Ended September 30, 2021 2020 Numerator: Net loss $ ( 9,744,444 ) $ ( 1,639,908 ) Denominator: Weighted-average number of common shares 15,868,421 8,187,517 Net loss per share applicable to common $ ( 0.61 ) $ ( 0.20 )
Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders	The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Nine Months Ended September 30, 2021 2020 Options to purchase shares of stock 3,630,044 3,369,144 Warrants to purchase shares of stock 1,561,913 650,948 Total 5,191,957 4,020,092

Liquidity and Going Concern - A

Liquidity and Going Concern - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 29, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2021	Dec. 31, 2020
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital					$ 43,161,479
Accumulated deficit					(24,776,068)	$ (15,031,624)
Cash					44,845,950	13,953,513
Accounts payable and accrued expenses					2,458,811
Notes payable					$ 248,911	318,995
Issuance of common stock	$ 1,932,618		$ 60,391	$ 4,871
Treasury share held	$ 519,813
June 2021 Offering
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital		$ 41,100,000
Issuance of common stock		$ 41,135,357
IPO
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital						$ 14,600,000

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Details)	Aug. 24, 2020$ / shares	Aug. 20, 2020	Sep. 30, 2021$ / shares	Sep. 30, 2020	Dec. 31, 2020$ / shares	Jun. 30, 2020$ / shares
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split ratio	0.8741	1.14396
Common stock, par value	$ 0.001		$ 0.001		$ 0.001	$ 5.50
Customer Concentration Risk | Sales Revenue | Minimum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			90.00%	90.00%

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrued consulting	$ 256,342	$ 115,405
Accrued legal and professional fees		383,286
Accrued research and development	1,483,479	83,491
Accrued interest	811	1,673
Accrued bonuses	152,860
Accrued other	11,518	49,079
Total accrued expenses and other current liabilities	$ 1,905,010	$ 632,934

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)	May 04, 2020	Feb. 05, 2020	Jan. 01, 2020	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Aug. 24, 2020	Jun. 13, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Notes Payable					$ 248,911	$ 318,995
Annual interest rate		1.59%
Shares subscribed for purchase				11,594
Share subscription price				$ 63,800
Common stock, par value				$ 5.50	$ 0.001	$ 0.001	$ 0.001
Notes payable outstanding balance					$ 248,911	$ 42,534
Strike price		$ 4.87			$ 3.75				$ 5.67
Issue date		Feb. 5, 2020
Notes payable, net of current portion					$ 0	276,461
Principal Balance
Debt Instrument [Line Items]
Notes payable, net of current portion					$ 248,911	248,911
2020 Note
Debt Instrument [Line Items]
Annual interest rate			5.25%
Debt instrument face amount			$ 103,586
Maturity date			Jan. 1, 2021
Settlement of notes including principal balance plus accrued and unpaid interest				$ 106,334
2019 Note
Debt Instrument [Line Items]
Settlement of principal amount			$ 98,419
Accrued interest			$ 5,167
Maturity date			Jan. 1, 2020
Fifth Restated Note
Debt Instrument [Line Items]
Notes Payable						42,534
Debt instrument face amount				$ 42,534
Notes payable outstanding balance						42,534
CEO Note
Debt Instrument [Line Items]
Annual interest rate		1.59%
Debt instrument face amount		$ 245,250
Net proceeds		$ 245,250
Maturity description					The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note.
Strike price		$ 4.87
Percentage of number of shares to value of loan		150.00%
On event of default					If an event of default occurs and is continuing, the Company agrees to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan.
C E O Restated Note
Debt Instrument [Line Items]
Notes Payable					$ 248,911	248,911
Annual interest rate								0.25%
Debt instrument face amount								$ 248,911
Strike price								$ 4.81
Paycheck Protection Program
Debt Instrument [Line Items]
Annual interest rate	1.00%
Debt instrument face amount						$ 27,550
Net proceeds	$ 27,550
Loan forgiveness terms					Some or all of this loan qualified for forgiveness if the Company expended not less than 60% of the loan proceeds on qualified payroll costs.
Paycheck Protection Program | Minimum
Debt Instrument [Line Items]
Percentage of loan proceeds expended on qualified payroll costs	60.00%

Notes Payable - Summary of Note

Notes Payable - Summary of Notes Payable Outstanding (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Notes Payable	$ 248,911	$ 318,995
Fifth Restated Note
Debt Instrument [Line Items]
Notes Payable		42,534
PPP Note
Debt Instrument [Line Items]
Notes Payable		27,550
CEO Restated Note
Debt Instrument [Line Items]
Notes Payable	$ 248,911	$ 248,911

Notes Payable - Summary of Futu

Notes Payable - Summary of Future Principal Payments on Notes Payable (Details)	Sep. 30, 2021USD ($)
Notes Payable [Abstract]
2022	$ 248,911
Total notes payable	$ 248,911

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) - Additional Information (Details)	Aug. 24, 2020$ / shares	Aug. 20, 2020	Jan. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)Vote$ / sharesshares	Sep. 30, 2020USD ($)shares	Dec. 31, 2020$ / sharesshares	Jun. 30, 2020$ / shares
Class Of Stock [Line Items]
Votes per each common stock share | Vote				1
Common stock shares reserved for issuance				5,191,957		4,318,357
Reverse stock split ratio	0.8741	1.14396
Common stock, par value | $ / shares	$ 0.001			$ 0.001		$ 0.001	$ 5.50
Reverse stock split description				On August 20, 2020, the board of directors adopted resolutions proposing that each 1.14396 shares of the Company’s issued and outstanding common stock, par value $0.001 per share, be automatically converted into one fully paid and non-assessable share of common stock, par value $0.001 (the “Reverse Stock Split”) with cash in lieu of fractional shares.
Proceeds from issuance of common stock | $				$ 41,135,357	$ 4,870
Additional rights or options granted			0
Issuance of common stock, stock options exercised, Shares					95,349
Consulting Services
Class Of Stock [Line Items]
Additional rights or options granted				0
Shares issued in exchange for consulting services				9,000
Fair value of stock issued in exchange for consulting services | $				$ 60,391
Consulting Services | Selling, General and Administrative
Class Of Stock [Line Items]
Fair value of stock issued in exchange for consulting services | $				$ 60,391
Private Placement
Class Of Stock [Line Items]
Issuance of common stock, Shares			874
Shares issued price per share | $ / shares			$ 5.57
Proceeds from issuance of common stock | $			$ 4,870
June 2021 Offering
Class Of Stock [Line Items]
Shares issued price per share | $ / shares				$ 3
Proceeds from issuance of common stock | $				$ 41,100,000
Issued and sold fully paid non-assessable shares of common stock				15,000,000
Offering costs, underwriting discounts and commissions | $				$ 3,900,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	Aug. 16, 2021	Jun. 25, 2021	Aug. 31, 2021	Jun. 30, 2021	May 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of stock options granted	27,240	90,708				68,628	0
Number of stock issued			21,853	21,854	73,496
Stock option, strike price	$ 1.79	$ 2.92	$ 2.02	$ 2.02	$ 0.38	$ 6.82
Stock option, aggregate grant date fair value	$ 50,000	$ 160,000				$ 259,674

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,266,026	$ 419,275
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	592,966	195,061
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 673,060	$ 224,214

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Feb. 05, 2020
Class Of Warrant Or Right [Line Items]
Class of warrant or right issued						26,225
Strike price	$ 3.75					$ 5.67	$ 3.75		$ 4.87
Contractual term						7 years
Fair value of warrant				$ 101,478				$ 101,478
Warrant expense	$ 181,762	$ 239,415	$ 237,768	$ 236,415	$ 89,515	$ 190,993	$ 658,945	$ 516,923
Class of warrant or right, date from which warrants or rights exercisable							Jun. 15, 2022
Class of warrant or right exercised in period							0	0
Underwriters
Class Of Warrant Or Right [Line Items]
Class of warrant or right issued							750,000
Fair value of warrant	$ 100						$ 100
Selling, General and Administrative
Class Of Warrant Or Right [Line Items]
Warrant expense							$ 658,945

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss	$ (4,471,197)	$ (2,636,179)	$ (2,637,068)	$ (670,599)	$ (421,869)	$ (547,440)	$ (9,744,444)	$ (1,639,908)
Denominator:
Weighted-average number of common shares outstanding - basic and diluted	25,143,559			8,198,754			15,868,421	8,187,517
Net loss per share applicable to common stockholders - basic and diluted	$ (0.18)			$ (0.08)			$ (0.61)	$ (0.20)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	5,191,957	4,020,092
Options to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	3,630,044	3,369,144
Warrants to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	1,561,913	650,948

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0